Rare Diseases Strategic Roundup: From Approval To Access | Aug 12 - Sep 16, 2026
Rare Disease Strategic Roundup exploring Developments and Competitive Shifts…
Women's Health Strategic Roundup | Aug 04 – Sep 08, 2026
Women's Health Strategic Roundup exploring Developments and Competitive Shifts…
Cell and Gene Therapy Strategic Roundup | Jul 29 – Aug 31, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Neuroscience Strategic Roundup | July 21–August 25, 2026
Neuroscience Strategic Roundup exploring Key Strategic Developments and…
Immunology Strategic Roundup | July 14 - August 18, 2026
Immunology Strategic Roundup exploring Key Strategic Developments and…
Rare Diseases Strategic Roundup | July 08 - Aug 12, 2026
Rare Disease Strategic Roundup exploring Developments and Competitive Shifts…
Cell and Gene Therapy Strategic Roundup | June 24–July 29, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Neuroscience Strategic Roundup | June17–July 21, 2026
Strategic Developments and Competitive Shifts in Neuroscience Coverage Period:…
Immunology Strategic Roundup | June 9–July 14, 2026
Key Strategic Developments and Competitive Shifts in Immunology Coverage: June…
Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
Warburg Pincus PANTHERx Rare Acquisition | Lucid Diligence Brief
Warburg Pincus to acquire control of PANTHERx Rare, backing expansion of the…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…